Dr Bruce Alan Snider, MD | |
510 Graves Ave Ste 210, Erlanger, KY 41018-3309 | |
(859) 341-5014 | |
(859) 341-5136 |
Full Name | Dr Bruce Alan Snider |
---|---|
Gender | Male |
Speciality | |
Experience | Years |
Location | 510 Graves Ave Ste 210, Erlanger, Kentucky |
Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1548331226 | NPI | - | NPPES |
64168354 | Medicaid | KY |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
2084P0800X | Psychiatry & Neurology - Psychiatry | 16835 (Kentucky) | Secondary |
174400000X | Specialist | 16835 (Kentucky) | Primary |
Mailing Address | Practice Location Address |
---|---|
Dr Bruce Alan Snider, MD 510 Graves Ave Ste 210, Erlanger, KY 41018-3309 Ph: (859) 341-5014 | Dr Bruce Alan Snider, MD 510 Graves Ave Ste 210, Erlanger, KY 41018-3309 Ph: (859) 341-5014 |
News Archive
"Charged by Secretary of State Hillary Clinton with developing a blueprint for the next phase of the U.S. government's involvement in the fight against HIV and AIDS, [U.S. Global AIDS Coordinator Ambassador Eric Goosby] ... will lead an interagency effort to give clearer meaning to the term, 'AIDS-free generation,' and provide a basis for programming," Sharon Stash, a senior fellow at the Center for Strategic & International Studies' (CSIS) Global Health Policy Center, writes in the CSIS "Smart Global Health" blog.
Some individuals experience cancer recurrence when they enter adolescence or adulthood after they have been successfully treated for cancer in childhood while others don't. But why is this? This is the core question being considered in a research project directed by the University Medical Center of Johannes Gutenberg University Mainz.
Computer science teacher Suzy Lebo saw covid-19 dangers frequently in her Indiana high school: classes with about 30 students sitting less than 18 inches apart. Students crowding teachers in hallways. Students and staff members taking off their masks around others.
BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that analysis of U.S. longitudinal patient-level claims data reveals the use of Bristol-Myers Squibb's oral Abilify as a first-line therapy for newly diagnosed schizophrenia patients continues to grow.
he Saving Lives at Birth: A Grand Challenge for Development recently shortlisted 53 finalists from around the world from more than 400 entries. Only 22 teams were awarded grants for their bold, new ideas to save the lives of mothers and newborns in developing countries.
› Verified 7 days ago